



Integra LifeSciences to Present At JPMorgan Healthcare Conference

PLAINSBORO, N.J., Jan 2, 2007 (PrimeNewswire via COMTEX News Network) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it is scheduled to present at the JPMorgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco at 9:00 AM PST on Monday, January 8, 2007.

The presentation will be delivered by Stuart Essig, President and Chief Executive Officer of Integra. A live webcast of this presentation can be accessed through a link provided in the Investor Relations section of Integra's website at <http://www.integra-LS.com>. Additionally, a replay of the webcast will be available through Monday, January 22, 2007.

The presentation will provide an overview of Integra's operations, with a focus on currently marketed products, sales distribution channels, and product pipeline, recent financial history, and Integra's overall business strategy for growth.

Integra LifeSciences Holdings Corporation is a diversified medical technology company that develops, manufactures, and markets medical devices for use in a variety of applications. The primary applications for our products are neurosurgery, reconstructive surgery and general surgery. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. Our corporate headquarters are in Plainsboro, New Jersey, and we have manufacturing and research facilities located throughout the world. Please visit our website at (<http://www.Integra-LS.com>).

Statements made at the upcoming conference may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Factors That May Affect Our Future Performance" included in the Business section of Integra's Annual Report on Form 10-K for the year ended December 31, 2005 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

This news release was distributed by PrimeNewswire, www.primenewswire.com

SOURCE: Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corporation
John B. Henneman, III, Executive Vice President,

Chief Administrative Officer

(609) 936-2481

jhenneman@Integra-LS.com

John Bostjancic, Vice President, Corporate Development

and Investor Relations

(609) 936-2239

jbostjancic@Integra-LS.com